Vir Biotechnology Inc (VIR)

Current ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019
Total current assets	US$ in thousands	1,588,230	1,769,180	1,946,330	2,358,630	2,519,080	2,413,620	2,288,270	2,567,550	1,562,820	1,066,340	862,295	993,114	772,365	849,572	578,761	377,541	402,995	337,720
Total current liabilities	US$ in thousands	175,407	165,050	225,623	485,288	511,029	308,203	477,868	702,361	341,242	233,724	146,024	361,099	99,064	76,998	54,940	56,396	59,206	44,316
Current ratio		9.05	10.72	8.63	4.86	4.93	7.83	4.79	3.66	4.58	4.56	5.91	2.75	7.80	11.03	10.53	6.69	6.81	7.62

December 31, 2023 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $1,588,230K ÷ $175,407K
= 9.05

The current ratio of Vir Biotechnology Inc has shown fluctuations over the past eight quarters. In Q4 2023, the current ratio was 9.05, which indicates that the company had $9.05 in current assets for every $1 in current liabilities. This was a decrease from the previous quarter but still remained at a relatively high level.

The current ratio was highest in Q3 2023 at 10.72, suggesting a strong liquidity position with ample current assets to cover short-term obligations. In contrast, Q1 2023 saw a current ratio of 4.86, representing a significant decrease in liquidity compared to the previous quarter.

Looking at the trend over the past two years, the current ratio has generally been increasing, with occasional fluctuations. Q2 2022 had a relatively low current ratio of 4.79, while Q3 2022 and Q4 2022 showed improvements.

Overall, the current ratio of Vir Biotechnology Inc has exhibited variability, but the company has generally maintained a healthy liquidity position with current assets exceeding current liabilities, providing a buffer against short-term financial obligations. However, management may need to closely monitor and manage working capital to ensure continued liquidity stability.